Efficacy of Adjunctive Treatments Added to Olanzapine or Clozapine for Weight Control in Patients with Schizophrenia: A Systematic Review and Meta-Analysis

Table 5

Meta-analysis of reboxetine ().

(a)

Number

First author

Concurrent therapy

Adjunctive agent (mg/day, daily max. dose)

Duration (weeks)

(drop)

Primary outcome

Secondary outcome

Weight reduction

Mean baseline

Mean change

Psychiatric evaluation

Mean baseline

Mean change

8

Poyurovsky (2007) [15]

Olanzapine

Reboxetine (4); placebo

6

31 (9); 28 (9)

BWT (kg)

67.1; 68.4

3.3; 4.9

0.013

SAPS

6.4; 5.8

−3.2; −3.1

0.96

13

Poyurovsky (2003) [19]

Olanzapine

Reboxetine (4); placebo

6

13 (3); 13 (3)

BWT (kg)

65.8; 59.8

2.4; 5.4

0.03

SAPS

23.2; 31.7

−18.4; −19.9

0.83

(b)

Number	First author	Statistics for each study					Difference in means and 95% CI	Relative weight
		Difference in means	Standard error	Variance	value	value
8; 13	Poyurovsky (2007) [15]; Poyurovsky (2003) [19]; Total	−1.600; −3.000; −1.862	0.624; 1.300; 0.563	0.389; 1.691; 0.316	−2.564; −2.307; −3.310	0.010; 0.021; 0.001		81.29; 18.71; 100.00

Heterogeneity: ; df = 1; = 0.33; = 0.00.